---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-001757"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:36:24.233278+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart receives $9.27M BARDA award for Phase 2b COVID pill vaccine; Nasdaq extends bid price compliance to July 2024

## Summary
- Vaxart awarded $9.27M from BARDA Project NextGen to prepare for a 10,000-subject Phase 2b study of its oral XBB COVID-19 vaccine vs. an approved mRNA comparator.
- Project NextGen is a $5B HHS initiative to develop innovative COVID vaccines and therapeutics providing broader, more durable protection.
- Nasdaq granted an additional 180-day compliance period until July 15, 2024 to meet the $1.00 minimum bid price requirement.
- Vaxart is considering options, including a reverse stock split, to regain compliance; no assurance of success is given.

## SEC filing metadata
- accession: 0001437749-24-001757
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774924001757/0001437749-24-001757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774924001757/vxrt20240119_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-001757
- JSON: https://secwatch.observer/filing/0001437749-24-001757.json
- Plain text: https://secwatch.observer/filing/0001437749-24-001757.txt

## Key facts
- Listing & Compliance Notices
  Vaxart, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: en notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Notice did not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until January 17, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Pursuant to the Extension Letter, the Company now has until July 15, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774924001757/0001437749-24-001757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.